These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8582435)

  • 21. Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis.
    Bocos C; Castro M; Quack G; Herrera E
    Biochim Biophys Acta; 1993 Jul; 1168(3):340-7. PubMed ID: 8323974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of short term lipid infusion on plasma and hepatic bile lipids in humans.
    Pakula R; Konikoff FM; Moser AM; Greif F; Tietz A; Gilat T; Rubin M
    Gut; 1999 Sep; 45(3):453-8. PubMed ID: 10446118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR
    Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B
    Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    Anderson P; Norbeck HE
    Eur J Clin Pharmacol; 1981; 21(3):209-14. PubMed ID: 7318880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diurnal rhythm of bile lipid composition after cholecystectomy and papillotomy. Postpapillotomy biliary lithogenicity.
    Kurtz W; Leuschner U; Schneider S; Classen M
    Scand J Gastroenterol; 1985 Oct; 20(8):1001-6. PubMed ID: 4081625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of bile acid pool size to biliary lipid excretion and the formation of lithogenic bile in man.
    Swell L; Bell CC; Vlahcevic ZR
    Gastroenterology; 1971 Nov; 61(5):716-22. PubMed ID: 5117636
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of fibric acid derivatives on biliary lipid composition.
    Palmer RH
    Am J Med; 1987 Nov; 83(5B):37-43. PubMed ID: 3318452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics.
    Wilson IR; Hurrell MA; Pattinson NR; Chapman BA
    J Gastroenterol Hepatol; 1994; 9(5):447-51. PubMed ID: 7827294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
    Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
    Betz E; Quack G
    Vasa; 1990; 19(2):157-60. PubMed ID: 2371790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
    Monk JP; Todd PA
    Drugs; 1987 Jun; 33(6):539-76. PubMed ID: 3301301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study.
    Noring L; Kjellin KG; Ledermann H
    J Int Med Res; 1981; 9(5):319-23. PubMed ID: 7297756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of gallbladder bile lithogenicity in patients with primary biliary cirrhosis.
    Fracchia M; Jazrawi RP; Galatola G
    Ital J Gastroenterol; 1996 Jun; 28(5):255-60. PubMed ID: 8842843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I; Summa JD
    Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biliary lipid secretion, bile acid metabolism, and gallstone formation are not impaired in hepatic lipase-deficient mice.
    Amigo L; Mardones P; Ferrada C; Zanlungo S; Nervi F; Miquel JF; Rigotti A
    Hepatology; 2003 Sep; 38(3):726-34. PubMed ID: 12939599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.